Trial Profile
A Phase II Study of Sequential Dose-Dense Chemotherapy and Dose-Intense Erlotinib for the Initial Treatment of Advanced Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Cisplatin; Docetaxel; Pegfilgrastim
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Jul 2013 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record (NCT00723138).
- 09 Jul 2013 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record (NCT00723138).
- 25 Jan 2013 Planned end date changed from 1 Sep 2011 to 1 Feb 2013 as reported by ClinicalTrials.gov record (NCT00723138).